Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Sol-Gel Technologies Ltd. reported a quarterly loss of $0.01 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.13, and an improvement from a loss of $0.21 per share a year ago, indicating a 92.31% earnings surprise [1] - The company achieved revenues of $5.36 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 99.29%, compared to revenues of $0.21 million in the same quarter last year [2] - Sol-Gel Technologies shares have declined approximately 54.8% year-to-date, contrasting with the S&P 500's gain of 24.7% [3] Financial Performance - Over the last four quarters, Sol-Gel Technologies has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $1.83 million, and for the current fiscal year, it is -$0.57 on revenues of $8.5 million [7] Industry Outlook - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Sol-Gel Technologies' stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]